Kansas Life Sciences Development Company

Kansas Life Sciences Development Company (KLSDC) is a development-stage biotechnology entity and a subsidiary of the University of Kansas Medical Center Research Institute. The company functions as a commercialization vehicle for medical research and faculty inventions originating from the University of Kansas. KLSDC holds significant intellectual property and financial interests in therapeutic programs, including the development of fosciclopirox for bladder cancer through its partner CicloMed and the licensing of arimoclomol to Orphazyme for neurodegenerative diseases. By bridging academic discovery and industry partnerships, KLSDC aims to advance novel therapies from the laboratory to clinical application.